Who
Keith Murphy
Executive Chairman
Company insider
Files Form 4 as: Executive Chairman, VivoSim Labs; Director, Matinas Biopharma Holdings; Director, TuHURA Biosciences.
In numbers
- Trades disclosed
- 65
- Buys
- 4
- Sells
- 10
- Bought
- $552K
- Sold
- $5.0M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 6 Aug 2012
- Last trade
- 27 Jan 2026
- Last filed
- 29 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Jan 2026filed 29 Jan 2026 | VIVS VivoSim LabsBiotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 27 Jan 2026filed 29 Jan 2026 | VIVS VivoSim LabsBiotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | MTNB Matinas Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,600 at $0.00 | filing |
| 7 Aug 2024filed 7 Aug 2024 | VIVS VivoSim LabsBiotechnology | SEC FORM 4 Code A | —19,607 at $0.00 | filing |
| 5 Aug 2024filed 7 Aug 2024 | VIVS VivoSim Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —574,923 at $0.00 | filing |
| 5 Aug 2024filed 7 Aug 2024 | VIVS VivoSim Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —143,731 at $0.00 | filing |
| 17 Nov 2023filed 17 Nov 2023 | VIVS VivoSim LabsBiotechnology | SEC FORM 4 Code A | —19,607 at $0.00 | filing |
| 10 Nov 2022filed 14 Nov 2022 | VIVS VivoSim LabsBiotechnology | SEC FORM 4 Code A | —19,607 at $0.00 | filing |
| 31 Aug 2022filed 20 Oct 2022 | VIVS VivoSim Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 7 Oct 2021filed 12 Oct 2021 | VIVS VivoSim Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 7 Oct 2021filed 12 Oct 2021 | VIVS VivoSim Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 7 Oct 2021filed 12 Oct 2021 | VIVS VivoSim Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 22 Sep 2021filed 22 Sep 2021 | HURA TuHURA Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 8 Mar 2021filed 10 Mar 2021 | VIVS VivoSim LabsBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 8 Mar 2021filed 10 Mar 2021 | VIVS VivoSim Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 8 Mar 2021filed 10 Mar 2021 | VIVS VivoSim Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 8 Mar 2021filed 10 Mar 2021 | VIVS VivoSim Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 15 Sep 2020filed 11 Dec 2020 | VIVS VivoSim Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 15 Sep 2020filed 17 Sep 2020 | HURA TuHURA Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 15 Sep 2020filed 17 Sep 2020 | VIVS VivoSim Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
News
Charles River Laboratories International (NYSE:CRL) versus VivoSim Labs (NASDAQ:VIVS) Head-To-Head ContrastVIVS · dailypolitical.com · 22 Oct 2026VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker ProfilingVIVS · manilatimes.net · 21 Oct 2026TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025HURA · prnewswire.com · 13 Oct 2026
0 headlines in the last 90 days name Keith Murphy; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.